Natco moves to oppose Gilead hepatitis C drug patent in India-source
April 10, 2014 at 08:38 AM EDT
MUMBAI, April 10 (Reuters) - India's Natco Pharma Ltd has formally asked the Indian patent office to deny U.S. drugmaker Gilead Sciences Inc's breakthrough hepatitis C drug Sovaldi a patent in India, a source with direct knowledge of the matter said.
